Aesculap, the world’s largest manufacturer of surgical instruments known for its innovations in neurosurgery, power systems and visualization, has launched XABO Antibiotic-Impregnated Catheters in the U.S. market which will help to significantly reduce the risk of shunt infections in hydrocephalus patients. This innovative product is designed to improve treatment for both pediatric and adult patients who suffer from this condition.
Health Technology Insights: PathAI and Northwestern Medicine Partner to Launch AI Pathology Platform
Hydrocephalus, characterized by excessive cerebrospinal fluid in the brain, affects over 1 million people in the United States. Shunt therapy, the most common treatment, often comes with the risk of infection,3 which impacts 7-15% of patients. These infections can impair quality of life, cognitive function and shunt survival.5
The XABO Antibiotic-Impregnated Catheters offer enhanced infection control, with clinical studies showing a two-thirds reduction in shunt infection rates as compared to standard catheters. The catheters continuously release antibiotics for a minimum of 38 days post-implantation, covering the critical period when patients are most vulnerable to infections. The XABO Antibiotic-Impregnated Catheter’s unique packaging allows for extended sterility, up to 36 months, as well as being able to withstand temperatures up to 86°F without losing their effectiveness.6 The high potency of clindamycin hydrochloride and rifampicin impregnation allows for low antibiotic dosage release which may reduce allergic reactions and minimize the risk of resistance development.
Health Technology Insights: WSP acquires specialist healthcare and life sciences consulting firm Lexica
“We are excited to introduce the XABO Antibiotic-Impregnated Catheters, which represent a significant advancement in the treatment of hydrocephalus,” said Bob Sowinski, Corporate Vice President, Aesculap. “This launch is key to our goal to improve patient outcomes and quality of life by reducing the incidence of shunt infections, a common and serious complication of hydrocephalus treatment.”
Health Technology Insights: Myriad Genetics Reveals New Data on Precise MRD Sensitivity
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
Source – PR Newswire
